A final common pathway for depression: Implications for therapy

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 8, 2007, Pages 1019-1032

  Stone, Eric A ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adrenoreceptor; Antidepressant; Corticosteroid

Indexed keywords

2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; 5 METHYLURAPIDIL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; ANTIDEPRESSANT AGENT; CORTICOSTEROID; CORTICOSTERONE; NIGULDIPINE;

BEHAVIOR; BRAIN FUNCTION; BRAIN REGION; DEPRESSION; HUMAN; HYPOTHESIS; LOW DRUG DOSE; MOTIVATION; NONHUMAN; REVIEW; STRESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; SIGNAL TRANSDUCTION;

EID: 34547730674     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.8.1019     Document Type: Review

References (160)

1. 2-adrenoceptor agonist denbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem. Pharmacol. (1989) 18:2957-2965.
2. WILLNER P: Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (1997) 134(4):319-329.
3. DEMYTTENAERE K, DE FRUYT J, STAHL SM: The many faces of fatigue in major depressive disorder. Int. J. Neuropsychopharmacol. (2005) 8(1):93-105.
4. MERRICK W: The experience of psychopathology: investigating mental disorders in their natural settings. In: Dysphoric Moods in Depressed and Non-depressed Adolescents. Vries MM (Ed.), Cambridge University Press, Cambridge, UK (1992):148-156.
5. SWANSON L: Cerebral hemisphere regulation of motivated behavior. Brain Res. (2000) 886:113-164.
6. DREVETS WC: Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders. Curr. Opin. Neurobiol. (2001) 11(2):240-249.
7. GOLDAPPLE K, SEGAL Z, GARSON C et al.: Modulation of cortical-limbic pathways in major depression - treatment-specific effects of cognitive behavior therapy. Arch. Gen. Psychiatry (2004) 61(1):34-41.
8. MAYBERG H, LIOTTI M, BRANNAN S et al.: Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am. J. Psychiatry (1999) 156(5):675-682.
9. MAYBERG HS, LOZANO AM, VOON V et al.: Deep brain stimulation for treatment-resistant depression. Neuron (2005) 45(5):651-660.
10. GOLD P, CHROUSOS G: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry. (2002) 7:254-262.
11. HOFFMAN GE, LYO D: Anatomical markers of activity in neuroendocrine systems: are we all 'fos-ed out'? J. Neuroendocrinol (2002) 14(4):259-268.
12. PASCOLI V, VALJENT E, CORBILLÉ AG et al.: cAMP and extracellular signal-regulated kinase signaling in response to D-amphetamine and methylphenidate in the prefrontal cortex in vivo: role of β1-adrenoceptors. Mol. Pharmacol. (2005) 68 (2):421-429.
13. STONE E, LEHMANN M, LIN Y, QUARTERMAIN D: Depressive behavior in mice due to immune stimulation is accompanied by reduced neural activity in brain regions involved in positively motivated behavior. Biol. Psychiatry (2006) 60:803-811.
14. STONE E, LEHMANN M, LIN Y, QUARTERMAIN D: Reduced evoked fos expression in activity-related brain regions in animal models of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry (2007) (In Press).
15. STONE E, LIN Y, AHSAN M, LEHMANN M, YERETSIAN J, QUARTERMAIN D: Role of CNS α-1 adrenoceptor activity in central fos responses to novelty. Synapse (2006) 59:299-307.
16. RHODES JS, GARLAND T Jr, GAMMIE SC: Patterns of brain activity associated with variation in voluntary wheel-running behavior. Behav. Neurosci. (2003) 117(6):1243-1256.
17. QUARTERMAIN D, LIN Y, STONE E: Central fos expression during the performance of a well-learned approach response. Submitted (2007).
18. KAREKEN DA, SABRI M, RADNOVICH AJ et al.: Olfactory system activation from sniffing:, effects in piriform and orbitofrontal cortex. Neuroimage (2004) 22(1):456-465.
19. SCHWEIMER J, SAFT S, HAUBER W: Involvement of catecholamine neurotransmission in the rat anterior cingulate in effort-related decision making. Behav. Neurosci. (2005) 119(6):1687-1692.
20. TABUCHI E, FURUSAWA AA, HORI E, UMENO K, ONO T, NISHIJO H: Neural correlates to action and rewards in the rat posterior cingulate cortex Neuroreport (2005) 16(9):949-953.
21. STONE E, LIN Y, AHSAN R, QUARTERMAIN D: Gross mapping of α1-adrenoceptors that regulate behavioral activation in the mouse brain. Behav. Brain Res. (2004) 152:167-175.
22. HERMAN JP, CULLINAN WE: Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci. (1997) 20(2):78-84.
23. CHIU TH, DUN SL, TANG H, DUN NJ: c-fos antisense attenuates Fos expression in rat central neurons induced by hemorrhage. Neuroreport (1994) 5:2178-2180.
24. PORSOLT RD, ANTON G, BLAVET N, JALFRE M: Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. (1978) 47:379-381.
25. DANTZER R: Cytokine, sickness behavior, and depression. Neurol. Clin. (2006) 24(3):441-460.
26. WEISS JM, BOSS-WILLIAMS KA, MOORE JP, DEMETRIKOPOULOS MK, RITCHIE JC, WEST CHK: Testing the hypothesis that locus coeruleus hyperactivity produces depression-related changes via galanin. Neuropeptides (2005) 39(3):281-287.
27. AVGUSTINOVICH DF, KOVALENKO IL, KUDRYAVTSEVA NN: A model of anxious depression: persistence of behavioral pathology. Neurosci. Behav. Physiol. (2005) 35(9):917-924.
28. DEPUE RA, IACONO WG: Neurobehavioral aspects of affective disorders. Ann. Rev. Psychol. (1989) 40:457-492.
29. DAVIDSON R: Affective style and affective disorders: perspectives from affective neuroscience. Cogn. Emot. (1998) 12:307-330.
30. SPENCER SJ, DAY TA: Role of catecholaminergic inputs to the medial prefrontal cortex in local and subcortical expression of Fos after psychological stress. J. Neurosci. Res. (2004) 78(2):279-288.
31. AMAT J, BARATTA MV, PAUL E, BLAND ST, WATKINS LR, MAIER SF: Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci (2005) 8(3):365-371.
32. BARBAS H, SAHA S, REMPEL-CLOWER N, GHASHGHAEI T: Serial pathways from primate prefrontal cortex to autonomic areas may influence emotional expression. BMC Neurosci. (2003) 4(1):25.
33. VALDÉS JL, FARÍAS P, OCAMPO-GARCÉS A, CORTÉS N, SERÓN-FERRÉ M, TORREALBA F: Arousal and differential Fos expression in histaminergic neurons of the ascending arousal system during a feeding-related motivated behaviour. Eur. J. Neurosci. (2005) 21(7):1931-1942.
34. REYES BAS, VALENTINO RJ, XU GP, VAN BOCKSTAELE EJ: Hypothalamic projections to locus coeruleus neurons in rat brain. Eur. J. Neurosci. (2005) 22(1):93-106.
35. FORRAY MI, GYSLING K: Role of noradrenergic projections to the bed nucleus of the stria terminalis in the regulation of the hypothalamic-pituitary-adrenal axis. Brain Res. Revs. (2004) 47(1-3):145-160.
36. VAN BOCKSTAELE EJ, BAJIC D, PROUDFIT H, VALENTINO RJ: Topographic architecture of stress-related pathways targeting the noradrenergic locus coeruleus. Physiol. Behav. (2001) 73(3):273-283.
37. VAN BOCKSTAELE EJ, PEOPLES J, TELEGAN P: Efferent projections of the nucleus of the solitary tract to peri-locus coeruleus dendrites in rat brain: evidence for a monosynaptic pathway. J. Comp. Neurol. (1999) 412(3):410-428.
38. STONE E, LIN Y, ITTEERA A, QUARTERMAIN D: Pharmacological evidence for the role of brain α1B-adrenergic receptors in the motor activity and spontaneous movement of mice. Neuropharmacolgy (2001) 40:254-261.
39. ZHANG HT, FRITH SA, WILKINS J, O'DONNELL JM: Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (2001) 159(1):89-97.
40. BERRIDGE CW, ISAAC SO, ESPAÑA RA: Additive wake-promoting actions of medial basal forebrain noradrenergic α1-and β-receptor stimulation. Behav. Neurosci. (2003) 117(2):350-359.
41. SCHWEIMER J, HAUBER W: Dopamine D1 receptors in the anterior cingulate cortex regulate effort-based decision making. Learn. Mem. (2006) 13(6):777-782.
42. ESPOSITO E: Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr. Drug Targets (2006) 7(2):177-185.
43. 1 receptor agonists in the mouse forced swim test. Br. J. Pharmacol. (1998) 123(7):1331-1336.
44. BING G, FILER D, MILLER JC, STONE EA: Noradrenergic activation of immediate early genes in rat cerebral cortex. Mol. Brain Res. (1991) 11:43-46.
45. O'NEILL MF, HICKS CA, SHAW G, PARAMESWARAN T, CARDWELL GP, O'NEILL MJ: Effects of 5-hydroxytryptamine, receptor antagonism on the behavioral activation and immediate early gene expression induced by dizocilpine. J. Pharmacol. Exp. Ther. (1998) 287(3):839-846.
46. KAUFFMAN AS, BUENZLE J, FRALEY GS, RISSMAN EF: Effects of galanin-like peptide (GALP) on locomotion, reproduction, and body weight in female and male mice. Horm. Behav. (2005) 48(2):141-151.
47. 1-adrenoceptors of the locus coeruleus in self-stimulation of the medial forebrain bundle. Neuropsychopharmacology (2007) 32:835-841.
48. DROUIN C, DARRACQ L, TROVERO F et al.: α1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. (2002) 22:2873-2884.
49. 1B-adrenergic receptor is expressed in neurons and NG2 oligodendrocytes. J. Comp. Neurol. (2004) 478(1):1-10.
50. 2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. Natl. Acad. Sci USA (1998) 95(2):735-740.
51. XU T, PANDEY SC: Cellular localization of serotonin(2A) (SHT(2A)) receptors in the rat brain. Brain Res. Bull. (2000) 51(6):499-505.
52. 2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse (1997) 27(1):79-82.
53. GOLDMAN-RAKIC PS, LIDOW MS, GALLAGER DW: Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J. Neurosci. (1990) 10:2125-2138.
54. SURMEIER DJ, SONG WJ, YAN Z: Coordinated expression of dopamine receptors in neostriatal medium spiny neurons. J. Neurosci. (1996) 16(20):6579-6591.
55. GRILLNER S, HELLGREN J, MENARD A, SAITOH K, WIKSTROM MA: Mechanisms for selection of basic motor programs - roles for the striatum and pallidum. Trends Neurosci. (2005) 28(7):364-370.
56. PAPAY R, GAIVIN R, JHA A et al.: Localization of the mouse α1A-adrenergic receptor (AR) in the brain: α1AAR is expressed in neurons, GABAergic interneurons, and NG2 oligodendrocyte progenitors. J. Comp. Neurol. (2006) 497(2):209-222.
57. PASQUALETTI M, ORI M, CASTAGNA M, MARAZZITI D, CASSANO GB, NARDI I: Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience (1999) 92(2):601-611.
58. VIJAYRAGHAVAN S, WANG M, BIRNBAUM SG, WILLIAMS GV, ARNSTEN AF: Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat. Neurosci. (2007) 10(3):376-384.
59. ARNSTEN AFT, MATHEW R, UBRIANI R, TAYLOR JR, BAO-MING L: α-1 Noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol. Psychiatry (1999) 45:26-31.
60. 1A receptor expression in pyramidal neurons of cortical and limbic brain regions. Cell Tissue Res. (2005) 321(2):159-172.
61. MACDONALD E, SCHEININ M: Distribution and pharmacology of α2-adrenoceptors in the central nervous system. J. Physiol. Pharmacol (1995) 46:241-258.
62. BOYSON SJ, MCGONIGLE P, MOLINOFF PB: Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. (1986) 6(11):3177-3188.
63. CAMPS M, CORTES R, GUEYE B, PROBST A, PALACIOS JM: Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience (1989) 28(2):275-290.
64. ARNSTEN AFT, CAI JX: Postsynaptic α-2 receptor stimulation improves memory in aged monkeys; indirect effects of yohimbine versus direct effects of clonidine. Neurobiol. Aging (1993) 14:597-603.
65. 1B receptor knockout mice in stress and anxiety paradigms. Behav. Pharmacol. (2003) 14(5-6):369-383.
66. STONE E, QUARTERMAIN D: α1-Noradrenergic neurotransmission, corticosterone and behavioral depression. Biol. Psychiatry (1999) 46:1287-1300.
67. 1-adrenergic, dopamine and serotonin systems. J. Neural Transm. (1999) 106(2):197-211.
68. OSSOWSKA G, NOWAK G, KATA R, KLENK-MAJEWSKA B, DANILCZUK Z, ZEBROWSKA-LUPINA F: Brain monoamine receptors in a chronic unpredictable stress model in rats. J. Neural Transm. (2001) 108(3):311-319.
69. 1A receptor downregulation by antidepressants in rat brain. Neurochem. Int. (2001) 38(7):573-579.
70. HUZARSKA M, ZIELINSKI M, HERMAN ZS: Repeated treatment with antidepressants enhances dopamine D1 receptor gene expression in the rat brain. Eur. J. Pharmacol. (2006) 532(3):208-213.
71. D'AQUILA PS, PEANA AT, CARBONI V, SERRA G: Different effect of desipramine on locomotor activity in quinpirole-treated rats after repeated restraint and chronic mild stress. Eur. J. Pharmacol. (2000) 399(1):43-47.
72. HOLSBOER F: Stress, hypercortisolism and corticosteroid receptors in depression: implicatons for therapy. J. Aff. Disord. (2001) 62(1-2):77-91.
73. SCHULE C: Neuroendocrinological mechanisms of actions of antidepressant drugs. J. Neuroendocrinol. (2007) 19(3):213-226.
74. DUMAN RS, MONTEGGIA LM: A neurotrophic model for stress-related mood disorders. Biol. Psychiatry (2006) 59(12):1116-1127.
75. FUCHS E, CZEH B, FLUGGE G: Examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews. Behav. Pharmacol. (2004) 15(5-6):315-325.
76. MCEWEN BS: Mood disorders and allostatic load. Biol Psychiatry (2003) 54(3):200-207.
77. BISAGNO V, FERRINI M, RIOS H, ZIEHER L, WIKINSKI S: Chronic corticosterone impairs inhibitory avoidance in rats: possible link with atrophy of hippocampal CA3 neurons. Pharmacol. Biochem. Behav. (2000) 66:235-240.
78. MCEWEN BS: The neurobiology of stress: from serendipity to clinical relevance. Brain Res. (2000) 886(1-2):172-189.
79. ALFONSO J, POLLEVICK GD, VAN DER HART MG, FLUGGE G, FUCHS E, FRASCH AC: Identification of genes regulated by chronic psychosocial stress and antidepressant treatment in the hippocampus. Eur. J. Neurosci. (2004) 19(3):659-666.
80. DE KLOET ER, SIBUG RM, HELMERHORST FM, SCHMIDT M: Stress, genes and the mechanism of programming the brain for later life. Neurosci. Biobehav. Revs. (2005) 29(2):271-281.
81. ARBORELIUS L, OWENS MJ, PLOTSKY PM, NEMEROFF CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. (1999) 160(1):1-12.
82. SHUMAKE J, EDWARDS E, GONZALEZ-LIMA F: Hypermetabolism of paraventricular hypothalamus in the congenitally helpless rat. Neurosci. Lett. (2001) 311(1):45-48.
83. SIEGLE GJ, THOMPSON W, CARTER CS, STEINHAUER SR, THASE ME: Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol. Psychiatry (2007) 61(2):198-209.
84. GREENWOOD BN, FOLEY TE, BURHANS D, MAIER SF, FLESHNER M: The consequences of uncontrollable stress are sensitive to duration of prior wheel running. Brain Res. (2005) 1033(2):164-178.
85. MARVEL FA, CHEN CC, BADR N, GAYKEMA RP, GOEHLER LE: Reversible inactivation of the dorsal vagal complex blocks lipopolysaccharide-induced social withdrawal and c-Fos expression in central autonomic nuclei. Brain Behav. Immunol. (2004) 18(2):123-134.
86. STOUT SC, MORTAS P, OWENS MJ, NEMEROFF CB, MOREAU JL: Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur. J. Pharmacol. (2000) 401(1):39-46.
87. GRANT MM, WEISS J: Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol. Psychiatry (2001) 49(2):117-129.
88. MAIER SF, WATKINS LR: Stressor controllability and learned helplessness: The roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Revs. (2005) 29(4-5):829-841.
89. MINOR T, HUANG Q, WITT A: Cytokine-purine interactions in tramuatic strss, behavioral depression, and sickness. CNS Neurol. Disord. Drug Targets (2006) 5:547-560.
90. GARCIA-SEVILLA JA, ESCRIBA PV, OZAITA A et al.: Up-regulation of immunolabeled α2A-adrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. (1999) 72(1):282-291.
91. MINOR TR, CHANG W-C, WINSLOW JL: Stress and adenosine: I. Effect of methylxanthine and amphetamine stimulants on learned helplessness in rats. Behav. Neurosci. (1994) 108:254-264.
92. SANACORA G, BERMAN RM, CAPPIELLO A et al.: Addition of the α2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. Neuropsychopharmacology (2004) 29(6):1166-1171.
93. DAYAS CV, BULLER KM, DAYTA: Hypothalamic paraventricular nucleus neurons regulate medullary catecholamine cell responses to restraint stress. J. Comp. Neurol. (2004) 478(1):22-34.
94. PERRIN D, MAMET J, GÉLOËN A, MOREL G, DALMAZ Y, PEQUIGNOT JM: Sympathetic and brain monoaminergic regulation of energy balance in obesity-resistant rats (Lou/C). Auton. Neurosci. (2003) 109(1-2):1-9.
95. KENNEY MJ, WEISS ML, PATEL KP, WANG Y, FELS RJ: Paraventricular nucleus bicuculline alters frequency components of sympathetic nerve discharge bursts. Am. J. Physiol. (2001) 281(3):H1233-H1241.
96. DELFS J, DRUHAN J, ASTON-JONES G: Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature (2000) 403:430-434.
97. DAVIS M, WALKER DL, LEE Y: Amygdala and bed nucleus of the stria terminalis: differential roles in fear and anxiety measured with the acoustic startle reflex. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1997) 352:1675-1687.
98. CRAIG AD: Human feelings: why are some more aware than others? Trends Cogn. Sci. (2004) 8(6):239-241.
99. HEINRICHS SC, KOOB GF: Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J. Pharmacol. Exp. Ther. (2004) 311(2):427-440.
100. MONNIKES H, HEYMANN-MONNIKES I, TACHE Y: CRF in the paraventricular nucleus of the hypothalamus induces dose-related behavioral profile in rats. Brain Res. (1992) 574(1-2):70-76.
101. BERNS GS, NEMEROFF CB: The neurobiology of bipolar disorder. Am. J. Med. Genet. C Semin. Med. Genet. (2003) 123(1):76-84.
102. JUTKIEWICZ EM, WOOD SK, HOUSHYAR H, HSIN LW, RICE KC, WOODS JH: The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (2005) 180(2):215-223.
103. OVERSTREET DH, KEENEY A, HOGG S: Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. Eur. J. Pharmacol. (2004) 492(2-3): 195-201.
104. 1-adrenergic receptors in the regulation of corticotropin - releasing hormone mRNA in the paraventricular nucleus of the hypothalamus during stress. Cell Mol. Neurobiol. (2000) 20(6):683-694.
105. CECCHI M, KHOSHBOUEI H, MORILAK DA: Modulatory effects of norepinephrine, acting on α1 receptors in the central nucleus of the amygdala, on behavioral and neuroendocrine responses to acute immobilization stress. Neuropharmacology (2002) 43(7):1139-1147.
106. CECCHI M, KHOSHBOUEI H, JAVORS M, MORILAK DA: Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience (2002) 112(1):13-21.
107. 2- and D-1-mechanisms of the basolateral nucleus of the amygdala enhance conditioned fear and impair unconditioned fear. Behav. Brain Res. (2007) 177(1):100-108.
108. ZIFA E, FILLION G: 5-Hydroxytryptamine receptors. Pharmacol. Rev. (1992) 44:401-458.
109. NYBERG L, ERIKSSON J, LARSSON A, MARKLUND P: Learning by doing versus learning by thinking:, an fMRI study of motor and mental training. Neuropsychologia (2006) 44(5):711-717.
110. GERSHON AA, VISHNE T, GRUNHAUS L: Dopamine D2-like receptors and the antidepressant response. Biol. Psychiatry (2007) 61 (2):145-153.
111. 1A agonists in the treatment of depression? Biol. Psychiatry (2003) 53(3):193-203.
112. ARNSTEN AFT, LI BM: Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry (2005) 57(11):1377-1384.
113. SIMSON PG, WEISS J, HOFFMAN LJ, AMBROSE MJ: Reversal of behavioral depression by infusion of an α-2 adrenergic agonist into the locus coeruleus. Neuropharmacology (1986) 25:385-389.
114. MAIER SF, GRAHN RE, WATKINS LR: 8-OH-DPAT microinjected in the region of the dorsal raphe nucleus blocks and reverses the enhancement of fear conditioning and interference with escape produced by exposure to inescapable shock Behav. Neurosci. (1995) 109:404-412.
115. KALIVAS PW, DUFFY P, LATIMER LG: Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. J. Pharmacol. Exp. Ther. (1987) 242(3):757-763.
116. KOSTOWSKI W: Two noradrenergic systems in the brain and their interactions with other monoaminergic neurons. Pol. J. Pharmacol. Pharm. (1979) 31(4):425-436.
117. CRYAN JF, PAGE ME, LUCKI I: Noradrenergic lesions differentially alter the antidepressant- like effects of reboxetine in a modified forced swim test. Eur. J. Pharmacol. (2002) 436(3):197-205.
118. WISOR JP, ERIKSSON KS: Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience (2005) 132(4):1027-1034.
119. CORNIL CA, BALTHAZART J, MOTTE P, MASSOTTE L, SEUTIN V: Dopamine activates noradrenergic receptors in the preoptic area. J. Neurosci. (2002) 22(21):9320-9330.
120. STONE E, LIN Y, QUARTERMAIN D: Possible dopaminergic stimulation of α-1 adrenoceptors in locus coeruleus involved in behavioral activation. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience (2007) (In Press).
121. 1-Adrenoceptor subtypes: a synopsis of their pharmacology and molecular biology. Drug Devel Res. (1996) 39:54-107.
122. NESTLER EJ, CARLEZON WA Jr. The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry (2006) 59(12):1151-1159.
123. NEMEROFF C: Recent advances in the neurobiology of depression. Psychopharmacol. Bull. (2002) 36(Suppl. 2):6-23.
124. HERMAN JP, MUELLER NK: Role of the ventral subiculum in stress integration. Behav. Brain Res. (2006) 174(2):215-224.
125. MUELLER MB, HOLSBOER F: Mice with mutations in the HPA-system as models for symptoms of depression. Biol. Psychiatry (2006) 59( 12):1104-1115.
126. DE KLOET ER, JOELS M, HOLSBOER F: Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci. (2005) 6(6):463-475.
127. DINAN TG, LAVELLE E, COONEY J et al.: Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr. Scand. (1997) 95(1):58-61.
128. DEBATTISTA C, POSENER JA, KALEHZAN BM, SCHATZBERG AF: Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebo-controlled study. Am. J. Psychiatry (2000) 157(8):1334-1337.
129. ARANA GW, SANTOS AB, LARAIA MT et al.: Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am. J. Psychiatry (1995) 152(2):265-267.
130. STONE E, LIN Y: An acute anti-immobility effect of exogenous corticosterone in mice. Submitted (2007).
131. LIN Y, STONE E, QUARTERMAIN D: Exogenous corticosterone has antidepressant activity in the forced swim test in mice. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience (2007) (In Press).
132. DEROCHE V, PIAZZA PV, MACCARI S, LE MOAL M, SIMON H: Repeated corticosterone administration sensitizes the locomotor response to amphetamine. Brain Res. (1992) 584:309-313.
133. SANDI C, VENERO C, GUAZA C: Novelty-related rapid locomotor effects of corticosterone in rats. Eur. J. Neurosci. (1996) 8(4):794-800.
134. TENK CM, KAVALIERS M, OSSENKOPP KP: The effects of acute corticosterone on lithium chloride-induced conditioned place aversion and locomotor activity in rats. Life Sci. (2006) 79(11):1069-1080.
135. SCHELLING G, BRIEGEL J, ROOZENDAAL B, STOLL C, ROTHENHÄUSLER HB, KAPFHAMMER HP: The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol. Psychiatry (2001) 50(12):978-985.
136. JOHNSON RW, PROPES MJ, SHAVIT Y: Corticosterone modulates behavioral and metabolic effects of lipopolysaccharide. Am. J. Physiol. (1996) 270(1):R192-R198.
137. STONE E, LIN Y, SUCKOW R, QUARTERMAIN D: Stress-induced subsensitivity to modafinil and its prevention by corticosteroids. Pharmacol. Biochem. Behav. (2002) 73:971-978.
138. HET S, WOLF OT: Mood changes in response to psychosocial stress in healthy young women: effects of pretreatment with cortisol. Behav. Neurosci. (2007) 121(1):11-20.
139. PEZESHKI G, POHLT, SCHOBITZ B: Corticosterone controls interleukin-1β expression and sickness behavior in the rat. J. Neuroendocrinol. (1996) 8:129-135.
140. CODDINGTON E, LEWIS C, ROSE JD, MOORE FL: Endocannabinoids mediate the effects of acute stress and corticosterone on sex behavior. Endocrinology (2007) 148(2):493-500.
141. REBER SO, BIRKENEDER L, VEENEMA AH et al.: Adrenal insufficiency and colonic inflammation after a novel chronic psycho-social stress paradigm in mice: implications and mechanisms. Endocrinology (2007) 148(2):670-682.
142. CARROLL BJ, CASSIDY F, NAFTOLOWITZ D et al.: Pathophysiology of hypercortisolism in depression. Acta Psychiatr. Scand. (2007) 115:90-103.
143. ARLT W, ALLOLIO B: Adrenal insufficiency. Lancet (2003) 361(9372):1881-1893.
144. GREGUS A, WINTINK AJ, DAVIS AC, KALYNCHUK LE: Effect of repeated corticosterone injections and restraint stress on anxiety and depression-like behavior in male rats. Behav. Brain Res. (2005) 156(1):105-114.
145. BROWN ES, SUPPES T: Mood symptoms during corticosteroid therapy: a review. Harv. Rev. Psychiatry (1998) 5(5):239-246.
146. BUCHMAN AL: Side effects of corticosteroid therapy. J. Clin. Gastroenterol. (2001) 33(4):289-294.
147. SONINO N, FAVA GA, RAFFI AR, BOSCARO M, FALLO F: Clinical correlates of major depression in Cushing's disease. Psychopathology (1998) 31(6):302-306.
148. MCEWEN BS: Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism (2005) 54(5):20-23.
149. MAKINO S, GOLD PW, SCHULKIN J: Corticosterone effects on corticotropin-releaseing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus. Brain Res. (1994) 640:105-112.
150. SCHAAF MJM, HOETELMANS RWM, DE KLOET ER, VREUGDENHIL E: Corticosterone regulates expression of BDNF and trkB but not NT-3 and trkC mRNA in the rat hippocampus. J. Neurosci. Res. (1997) 48(4):334-341.
151. BERTON O, MCCLUNG CA, DILEONE RJ et al.: Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science (2006) 311(5762):864-868.
152. ZEBROWSKA-LUPINA I: Presynaptic α-adrenoceptors and the action of tricyclic antdepressant drugs in behavioural despair in rats. Psychopharmacology (1980) 71:169-172.
153. BALLESTEROS J, CALLADO LF: Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Aff. Disord. (2004) 79(1-3):137-147.
154. HARRIS AHS, CRONKITE R, MOOS R: Physical activity, exercise coping, and depression in a 10-year cohort study of depressed patients. J. Aff. Disord. (2006) 93(1-3):79-85.
155. KOH S, MAGID R, CHUNG H, STINE CD, WILSON DN: Depressive behavior and selective downregulation of serotonin receptor expression after early-life seizures: reversal by environmental enrichment. Epilepsy Behav. (2007) 10(1):26-31.
156. DUNCAN GE, BREESE GR, CRISWELL H, STUMPF WE, MUELLER RA, COVEY JB: Effects of antidepressant drugs injected into the amygdala on behavioral responses of rats in the forced swim test. J. Pharmacol. Exp. Ther. (1986) 238:758-762.
157. KARST H, BERGER S, TURIAULT M, TRONCHE F, SCHUTZ G, JOELS M: Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc. Natl. Acad. Sci. USA (2005) 102(52):19204-19207.
158. DI S, MALCHER-LOPES R, MARCHESELLI VL, BAZAN NG, TASKER JG: Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and γ-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology (2005) 146(10):4292-4301.
159. KROES RA, PANKSEPP J, BURGDORF J, OTTO NJ, MOSKAL JR: Modeling depression: social dominance-submission gene expression patterns in rat neocortex. Neuroscience (2006) 137(1):37-49.
160. TSANKOVA NM, BERTON O, RENTHAL W, KUMAR A, NEVE RL, NESTLER EJ: Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. (2006) 9(4):519-525.